Inhibition of HDAC6 activity in kidney diseases: a new perspective

Area of Science:

• Biochemistry
• Molecular Biology
• Nephrology

Background:

• Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme crucial for protein deacetylation.
• HDAC6 uniquely targets cytoplasmic proteins and has deacetylation-independent functions.
• Elevated HDAC6 expression and activity are observed in various kidney diseases.

Purpose of the Study:

• To explore the role of HDAC6 in kidney diseases.
• To review the therapeutic potential of HDAC6 inhibitors in nephrology.
• To address challenges in selectively targeting HDAC6 for renoprotection.

Main Methods:

• Literature review of studies on HDAC6 in kidney disease.
• Analysis of HDAC6 expression and activity in disease models.
• Evaluation of preclinical data on HDAC6 inhibitors for kidney treatment.

Main Results:

• HDAC6 activity is increased in autosomal dominant polycystic kidney disease (ADPKD), renal fibrosis, and acute kidney injury (AKI).
• HDAC6 inhibitors have demonstrated efficacy in limiting kidney disease progression in preclinical studies.
• Targeting HDAC6 presents a potential novel therapeutic strategy for kidney diseases.

Conclusions:

• HDAC6 plays a significant role in the pathogenesis of kidney diseases.
• HDAC6 inhibitors offer a promising avenue for novel kidney disease treatments.
• Further research is needed to selectively harness the renoprotective effects of HDAC6 inhibition.